CLOs on the Move

Dewpoint Therapeutics

www.dewpointx.com

 
Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Nitrome Biosciences

Nitrome Biosciences has discovered and identified a new class of enzymes.

GluStitch

GluStitch, Inc. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BIOSPECTRA

BIOSPECTRA, INC. is a Stroudsburg, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Minerva Neurosciences

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe are innovative mechanisms of action. Our executive management team includes globally recognized specialists in central nervous system diseases addressing significant unmet medical needs. Our strategy is based on the following key principles: • Develop differentiated products based on biological and clinical insights related to the unmet needs of patients; • Conduct proof-of-principle trials in geographic areas with well characterized and validated patient populations where we have access to highly trained physicians with experience in conducting CNS-related trials; • Leverage the randomized, double-blind, placebo-controlled data from these trials to advance the clinical development of our products in multiple regulatory jurisdictions; • Selectively explore collaborations with leading pharmaceutical companies to maximize the value of our current product candidate portfolio, particularly in connection with the initiation of pivotal Phase III clinical trials and subsequent regulatory review, approval and commercialization; • Apply our management team`s expertise and current intellectual property portfolio to identify and explore additional indications relating to our current portfolio of compounds and to acquire additional product candidates

Progenitor Cell Therapy

Progenitor Cell Therapy, LLC, a cell therapy services company, supports the development and commercialization of cellular therapies. It offers manufacturing practices-compliant services for pre-clinical and clinical development, as well as involves in the commercialization of cellular therapies for clients in the United States and internationally.